Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N, Fasching PA, Wuerstlein R, Degenhardt T, Lüftner D, Kates RE, Schumacher J, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Schinköthe T, Schmidt M; AGO-B WSG PreCycle investigators (see Appendix 1). Harbeck N, et al. Among authors: kates re. Ann Oncol. 2023 Aug;34(8):660-669. doi: 10.1016/j.annonc.2023.05.003. Epub 2023 May 16. Ann Oncol. 2023. PMID: 37201751 Free article. Clinical Trial.
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
Degenhardt T, Fasching PA, Lüftner D, Müller V, Thomssen C, Schem C, Witzel I, Decker T, Tesch H, Kümmel S, Uleer C, Wuerstlein R, Hoffmann O, Warm M, Marschner N, Schinköthe T, Kates RE, Schumacher J, Otremba B, Zaiss M, Harbeck N, Schmidt M; PreCycle Investigators. Degenhardt T, et al. Among authors: kates re. Trials. 2023 May 17;24(1):338. doi: 10.1186/s13063-023-07306-z. Trials. 2023. PMID: 37198674 Free PMC article. Clinical Trial.
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
Gluz O, Nitz UA, Christgen M, Kuemmel S, Holtschmidt J, Schumacher J, Hartkopf A, Potenberg J, Lüedtke-Heckenkamp K, Just M, Schem C, von Schumann R, Kolberg-Liedtke C, Eulenburg CZ, Schinköthe T, Graeser M, Wuerstlein R, Kates RE, Kreipe HH, Harbeck N. Gluz O, et al. Among authors: kates re. JAMA Oncol. 2023 Jul 1;9(7):946-954. doi: 10.1001/jamaoncol.2023.0646. JAMA Oncol. 2023. PMID: 37166817 Free PMC article. Clinical Trial.
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
Nitz UA, Gluz O, Kümmel S, Christgen M, Braun M, Aktas B, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C, Darsow M, Krauss K, Nuding B, Thill M, Potenberg J, Uleer C, Warm M, Fischer HH, Malter W, Hauptmann M, Kates RE, Gräser M, Würstlein R, Shak S, Baehner F, Kreipe HH, Harbeck N. Nitz UA, et al. Among authors: kates re. J Clin Oncol. 2022 Aug 10;40(23):2557-2567. doi: 10.1200/JCO.21.02759. Epub 2022 Apr 11. J Clin Oncol. 2022. PMID: 35404683
Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet.
Kolberg-Liedtke C, Wuerstlein R, Gluz O, Heitz F, Freudenberger M, Bensmann E, du Bois A, Nitz U, Pelz E, Warm M, Ortmann M, Sultova E, Brucker SY, Kates RE, Fehm T, Harbeck N. Kolberg-Liedtke C, et al. Among authors: kates re. Breast Care (Basel). 2021 Oct;16(5):475-483. doi: 10.1159/000512416. Epub 2020 Dec 15. Breast Care (Basel). 2021. PMID: 34720807 Free PMC article.
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
Harbeck N, von Schumann R, Kates RE, Braun M, Kuemmel S, Schumacher C, Potenberg J, Malter W, Augustin D, Aktas B, Forstbauer H, Tio J, Grischke EM, Biehl C, Liedtke C, De Haas SL, Deurloo R, Wuerstlein R, Kreipe HH, Gluz O. Harbeck N, et al. Among authors: kates re. Cancers (Basel). 2021 Sep 29;13(19):4884. doi: 10.3390/cancers13194884. Cancers (Basel). 2021. PMID: 34638369 Free PMC article.
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.
Wuerstlein R, Harbeck N, Grischke EM, Forstmeyer D, von Schumann R, Krabisch P, Lüdtke-Heckenkamp K, Stefek A, Stoetzer O, Grafe A, Kaltenecker G, Forstbauer H, Augustin D, Schrader I, Tio J, Nitz U, Gluz O, Kates RE, Graeser MK. Wuerstlein R, et al. Among authors: kates re. Breast Care (Basel). 2021 Feb;16(1):50-58. doi: 10.1159/000506622. Epub 2020 Apr 6. Breast Care (Basel). 2021. PMID: 33716632 Free PMC article.
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
Nitz U, Gluz O, Kreipe HH, Christgen M, Kuemmel S, Baehner FL, Shak S, Aktas B, Braun M, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Nuding B, Darsow M, Schumacher C, Krauss K, Malter W, Thill M, Warm M, Wuerstlein R, Kates RE, Harbeck N. Nitz U, et al. Among authors: kates re. Ther Adv Med Oncol. 2020 Nov 23;12:1758835920973130. doi: 10.1177/1758835920973130. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33281950 Free PMC article.
125 results